[1]. Davis, R., K. Deak and C.H. Glass, Pulmonary Granular Cell Tumors: A Study of 4 Cases Including a Malignant Phenotype. Am J Surg Pathol, 2019. 43(10): p. 1397-1402.
[2]. Stemm, M., et al., Typical and Atypical Granular Cell Tumors of Soft Tissue: A Clinicopathologic Study of 50 Patients. Am J Clin Pathol, 2017. 148(2): p. 161-166.
[3]. Rubino, F., et al., Granular cell tumors of the sellar region: what should be done after subtotal resection? A systematic review. Pituitary, 2020. 23(6): p. 721-732.
[4]. Aoyama, K., et al., Granular cell tumors: a report of six cases. World J Surg Oncol, 2012. 10: p. 204.
[5]. Shi, Y., et al., Experience with Esophageal Granular Cell Tumors: Clinical and Endoscopic Analysis of 22 Cases. Dig Dis Sci, 2020.
[6]. Lee, C., et al., Clinicopathologic Features of Benign Neurogenic Tumor of Urinary Bladder. Int J Surg Pathol, 2018. 26(3): p. 221-228.
[7]. Sun, Y., et al., Granular Cell Tumor of the Bladder: A Report of Six Cases. Urology, 2018. 121: p. 203.e1-203.e5.
[8]. Yoshida, T., et al., Granular cell tumor of the urinary bladder. Int J Urol, 2001. 8(1): p. 29-31.
[9]. Eandi, J.A., et al., Granular cell tumor of the urinary bladder with pseudoepitheliomatous hyperplasia and colocalization with adenocarcinoma. Int J Urol, 2007. 14(9): p. 862-4.
[10]. Shah, K., et al., Malignant Granular Cell Tumor of the Lower Extremity in an Adolescent Male. J Pediatr Hematol Oncol, 2020.
[11]. Stasek, M., et al., Malignant Granular Cell Tumor of the Esophagus: A Case Report. Ann Thorac Cardiovasc Surg, 2020. 26(6): p. 359-364.
[12]. Bradford, B.E., et al., Benign and Malignant Granular Cell Tumor of the Hypopharynx: Two Faces of a Rare Entity. Head Neck Pathol, 2020.
[13]. Tsukamoto, S., et al., Malignant granular cell tumor of the median nerve: a case report with a literature review of 157 cases. Skeletal Radiol, 2019. 48(2): p. 307-316.
[14]. Jia, X., et al., Large malignant granular cell tumor with suprascapular nerve and brachial plexus invasion: A case report and literature review. Medicine (Baltimore), 2017. 96(44): p. e8531.
[15]. Akahane, K., et al., Malignant granular cell tumor of the breast: case report and literature review. Breast Cancer, 2015. 22(3): p. 317-23.
[16]. Liu, T.T., et al., Primary cutaneous malignant granular cell tumor: a case report in China and review of the literature. Diagn Pathol, 2015. 10: p. 113.
[17]. Zhuang, Y.Z., X.Y. Jiang and P.Q. Chen, [Malignant granular cell tumor of the urinary bladder]. Zhonghua Bing Li Xue Za Zhi, 2006. 35(3): p. 188.
[18]. Davis, R., K. Deak and C.H. Glass, Pulmonary Granular Cell Tumors: A Study of 4 Cases Including a Malignant Phenotype. Am J Surg Pathol, 2019. 43(10): p. 1397-1402.
[19]. Pareja, F., et al., Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors. Nat Commun, 2018. 9(1): p. 3533.
[20]. Wei, L., et al., Whole-genome sequencing of a malignant granular cell tumor with metabolic response to pazopanib. Cold Spring Harb Mol Case Stud, 2015. 1(1): p. a000380.
[21]. Fanburg-Smith, J.C., et al., Malignant granular cell tumor of soft tissue: diagnostic criteria and clinicopathologic correlation. Am J Surg Pathol, 1998. 22(7): p. 779-94.
[22]. Fanburg-Smith, J.C., et al., Malignant granular cell tumor of soft tissue: diagnostic criteria and clinicopathologic correlation. Am J Surg Pathol, 1998. 22(7): p. 779-94.
[23]. Quinn, P.L., et al., Malignant Granular Cell Tumor of the Bile Duct. ACG Case Rep J, 2019. 6(8): p. e00193.
[24]. Moten, A.S., et al., Malignant granular cell tumor: Clinical features and long-term survival. J Surg Oncol, 2018. 118(6): p. 891-897.
[25]. Xu, S., et al., Next Generation Sequencing Uncovers Potential Genetic Driver Mutations of Malignant Pulmonary Granular Cell Tumor. J Thorac Oncol, 2015. 10(10): p. e106-9.
[26]. Attar, N. and S.K. Kurdistani, Exploitation of EP300 and CREBBP Lysine Acetyltransferases by Cancer. Cold Spring Harb Perspect Med, 2017. 7(3).
[27]. Breen, M.E. and A.K. Mapp, Modulating the masters: chemical tools to dissect CBP and p300 function. Curr Opin Chem Biol, 2018. 45: p. 195-203.
[28]. Blobel, G.A., CREB-binding protein and p300: molecular integrators of hematopoietic transcription. Blood, 2000. 95(3): p. 745-55.
[29]. Scialdone, A., et al., Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies. Exp Hematol, 2019. 79: p. 35-46.e1.
[30]. Huang, Y., et al., The Leukemogenic TCF3-HLF Complex Rewires Enhancers Driving Cellular Identity and Self-Renewal Conferring EP300 Vulnerability. Cancer Cell, 2019. 36(6): p. 630-644.e9.
[31]. Yang, Y., et al., Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors. J Med Chem, 2020. 63(3): p. 1337-1360.
[32]. Bi, Y., et al., EP300 as an oncogene correlates with poor prognosis in esophageal squamous carcinoma. J Cancer, 2019. 10(22): p. 5413-5426.
[33]. Zhu, G., et al., EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients. Aging (Albany NY), 2020. 12(3): p. 2132-2141.
[34]. Zhang, H., et al., DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients. Med Oncol, 2007. 24(2): p. 251-8.
[35]. Nebert, D.W., et al., NAD(P)H: quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review. Genet Med, 2002. 4(2): p. 62-70.
[36]. Almoguera, B., et al., Imputation of TPMT defective alleles for the identification of patients with high-risk phenotypes. Front Genet, 2014. 5: p. 96.
[37]. Li, D., et al., Effects of base excision repair gene polymorphisms on pancreatic cancer survival. Int J Cancer, 2007. 120(8): p. 1748-54.
[38]. Alnashwan, Y.A., K. Ali and S.S. Amr, Metastasizing Malignant Granular Cell Tumor (Abrikossoff Tumor) of the Anterior Abdominal Wall, with Prolonged Survival. Case Rep Pathol, 2019. 2019: p. 9576487.